1. Home
  2. TCRX

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 98.5M IPO Year: 2021
Target Price: $9.83 AVG Volume (30 days): 437.3K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.25 EPS Growth: N/A
52 Week Low/High: $1.34 - $9.69 Next Earning Date: 03-05-2025
Revenue: $2,816,000 Revenue Growth: -86.62%
Revenue Growth (this year): 32.21% Revenue Growth (next year): 118.35%

TCRX Daily Stock ML Predictions

Share on Social Networks: